Table C-32. Ongoing clinical trial of brimonidine intravitreal implant

Clinicaltrials.gov Title Clinicaltrials.gov Identifier Sponsor	Study Design	Purpose	Start Date Expected Completion Date Estimated Enrollment	Primary Outcomes	Secondary Outcomes	Eye-specific Inclusion Criteria	Eye-specific Exclusion Criteria
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON) NCT02087085 Allergan	Triple-masked (patient, investigator, outcome assessor), randomized parallel-assignment, sham-controlled study	This study will assess the safety and efficacy of the brimonidine intravitreal implant in patients with geographic atrophy due to AMD.	May 2014 February 2019 Recruiting patients n=300	Change from baseline in atrophic lesion area in the study eye through month 24	Change from baseline in low luminance BCVA in the study eye through month 24, change from baseline in retinal sensitivity in the study eye through month 24	Geographic atrophy due to AMD in the study eye Visual acuity better than or equal to 20/80 in the study eye and 20/200 in the fellow eye	Cataract surgery or LASIK in the study eye in the past 3 months Infection in either eye in the past 3 months

AMD=age-related macular degeneration; BCVA=best-corrected visual acuity; LASIK=laser assisted in-situ keratomileusis; RP=retinitis pigmentosa